Related to Galapagos Earns Just Over $5M from Merck & Co. for Achieving Milestones in Metabolic and Inflammatory Disease Deals

• Feature Articles: Addressing Unmet Type 2 Diabetes Needs
  
• Assay Tutorials: Machine Vision Improves HTS Quality Control
  
• Point of View: New Treatment Strategies for Inflammation Gain Ground
  
• Feature Articles: Getting a Handle on Metabolic Disorders
  
• Feature Articles: Search Intensifies for Diabetes Drugs
  
• Tech Notes: Developments in Focused Kinase Libraries
  
• Corporate Profiles: Transforming Inflammatory Disease Therapies
  
• Feature Articles: Small Molecule Simplicity Gives Them Staying Power
  
• Feature Articles: Obesity Proving Complicated and Personal
  
• BioPerspectives: Mandated HPV Vaccines? Why Not?
  
• BioPerspectives: Emerging Insights into the Role of the Skeleton
  
• Wall Street BioBeat: Type 2 Diabetes Drugs Drive Sector Growth
  
• BioPerspectives: Addressing Unmet Medical Needs with Complex Carbohydrate Chemistry